Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-low status confers therapeutic sensitivity to Trastuzumab deruxtecan in patients with Invasive Breast Carcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.